Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 1
1992 5
1993 8
1994 11
1995 13
1996 27
1997 9
1998 12
1999 11
2000 21
2001 18
2002 24
2003 25
2004 29
2005 45
2006 33
2007 32
2008 42
2009 63
2010 49
2011 56
2012 70
2013 60
2014 67
2015 78
2016 56
2017 42
2018 45
2019 43
2020 56
2021 35
2022 46
2023 42
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

1,067 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Lancet Diabetes Endocrinol. 2014. PMID: 24948511 Clinical Trial.
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was -0.11% (95% CI -0.19 to -0.02; p=0.0153 for superiority). Adverse events were reported …
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in Hb …
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.
Park HK, Kim KA, Min KW, Sohn TS, Jeong IK, Ahn CW, Kim NH, Park IB, Cho HC, Chung CH, Choi SH, Park KS, Yang SO, Lee KW. Park HK, et al. Diabetes Obes Metab. 2023 Sep;25(9):2743-2755. doi: 10.1111/dom.15164. Epub 2023 Jun 20. Diabetes Obes Metab. 2023. PMID: 37337747 Clinical Trial.
RESULTS: Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) completed the study. Over 52 weeks, the dapagliflozin group showed the following differences versus the glimepiride group: -2.59 kg B …
RESULTS: Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) …
Glimepiride pharmacokinetics in overdose.
Mégarbane B, Abe E, Chevillard L. Mégarbane B, et al. Clin Toxicol (Phila). 2022 Nov;60(11):1284-1285. doi: 10.1080/15563650.2022.2112692. Epub 2022 Aug 18. Clin Toxicol (Phila). 2022. PMID: 35980254 No abstract available.
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ, Lee DH, Jeon HJ, Oh TK. Ku EJ, et al. Diabetes Res Clin Pract. 2019 May;151:65-73. doi: 10.1016/j.diabres.2019.04.008. Epub 2019 Apr 4. Diabetes Res Clin Pract. 2019. PMID: 30954510
METHODS: This study was an open-labeled, prospective, 52-week study conducted in T2D patients with glycated hemoglobin (HbA(1c)) ranging 7.5-12.0% with metformin, glimepiride and dipeptidyl peptidase-4 inhibitors. Patients were divided into either empagliflozin (25 mg/day) …
METHODS: This study was an open-labeled, prospective, 52-week study conducted in T2D patients with glycated hemoglobin (HbA(1c)) ranging 7.5 …
Clinical review of glimepiride.
McCall AL. McCall AL. Expert Opin Pharmacother. 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. Expert Opin Pharmacother. 2001. PMID: 11336617 Review.
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment of Type 2 diabetes mellitus (DM). Glimepiride therapy ameliorates the relative insulin secretory deficit found in most patients with …
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment …
Pioglitazone hydrochloride/glimepiride.
Blake EW. Blake EW. Drugs Today (Barc). 2007 Jul;43(7):487-97. doi: 10.1358/dot.2007.43.7.1073850. Drugs Today (Barc). 2007. PMID: 17728849 Review.
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines are in place to limit patient selection for the use of pioglitazone based on cardiac risk factors. In general, pioglitazone and glimepir …
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines …
[Glimepiride].
Nakamura N. Nakamura N. Nihon Rinsho. 2002 Sep;60 Suppl 9:351-6. Nihon Rinsho. 2002. PMID: 12387017 Review. Japanese. No abstract available.
Clinical profile of glimepiride.
Draeger E. Draeger E. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S139-46. doi: 10.1016/0168-8227(95)01072-l. Diabetes Res Clin Pract. 1995. PMID: 8529506 Review.
In patients, glimepiride had a more rapid onset of action than glibenclamide, with a long duration of action. Glimepiride achieved metabolic control with the lowest dose (1-8 mg daily) of all the sulphonylureas. ...
In patients, glimepiride had a more rapid onset of action than glibenclamide, with a long duration of action. Glimepiride achi …
Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD, Balfour JA. Langtry HD, et al. Drugs. 1998 Apr;55(4):563-84. doi: 10.2165/00003495-199855040-00007. Drugs. 1998. PMID: 9561345 Review.
Glimepiride was similar in efficacy to glibenclamide and glipizide in 1-year studies. However, glimepiride appears to reduce blood glucose more rapidly than glipizide over the first few weeks of treatment. ...
Glimepiride was similar in efficacy to glibenclamide and glipizide in 1-year studies. However, glimepiride appears to reduce b …
The role of glimepiride in the treatment of type 2 diabetes mellitus.
Briscoe VJ, Griffith ML, Davis SN. Briscoe VJ, et al. Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):225-35. doi: 10.1517/17425250903512955. Expert Opin Drug Metab Toxicol. 2010. PMID: 20055691 Review.
AREAS COVERED IN THIS REVIEW: This article reviews the pharmacological and clinical aspects of glimepiride, a second-generation sulfonylurea. Literature search was conducted in PubMed, and articles selected for relevance to pharmacology or clinical efficacy data fro …
AREAS COVERED IN THIS REVIEW: This article reviews the pharmacological and clinical aspects of glimepiride, a second-generation sulfo …
1,067 results